liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study
Karolinska University Hospital, Lung Diseases, Solna, Stockholm.
Finsen Institute, Department of Oncology, National University Hospital/Finsen Institute, Copenhagen, Denmark.
Regional Hospital, Trondheim, Norway.
Östergötlands Läns Landsting, Kirurgi- och onkologicentrum, Lungmedicinska kliniken US. Linköpings universitet, Institutionen för klinisk och experimentell medicin. Linköpings universitet, Hälsouniversitetet.
2008 (Engelska)Ingår i: The Clinical Respiratory Journal, ISSN 1752-6981, Vol. 2, nr 2, s. 80-85Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Introduction: Malignant pleural mesothelioma (MPM) has a poor prognosis and there is limited effect of treatment. Lately, pemetrexed and cisplatin have been established as the standard treatment.

Objectives: The present study was planned in 1998, when there was no standard treatment. Single-dose doxorubicine had, in small studies, accomplished remissions, and the Scandinavian Mesothelioma Groups therefore decided to test a liposomized form of this drug, which had shown limited toxicity but good efficacy in a few small studies.

Methods: Fifty-four evaluable patients with histologically verified and inoperable MPM were treated with liposomized doxorubicine 40 mg/m2, every 4 weeks for six cycles.

Results: In all, 29 patients (54%) received at least six treatments. The quality of life remained good during the study. Hematologic toxicity was very low. Palmo–plantar erythema occurred in 11 patients (20%), thereof 7 grade II but none was severe and none was dose-limiting. There were four partial responses (7%). The median time to progression (TTP) was 5 months, the median survival was 12 months, and at 24 months, 22% were still alive.

Conclusion: Liposomized doxorubicine has a low toxicity and is well tolerated; there were a remarkably long TTP and a good survival. Thus, despite the low response rate, liposomized doxorubicine remains an interesting drug for the treatment of malignant mesothelioma.

Ort, förlag, år, upplaga, sidor
2008. Vol. 2, nr 2, s. 80-85
Nyckelord [en]
liposomized doxorubicine - mesothelioma - phase II study - treatment
Nationell ämneskategori
Medicin och hälsovetenskap
Identifikatorer
URN: urn:nbn:se:liu:diva-21807DOI: 10.1111/j.1752-699X.2008.00050.xOAI: oai:DiVA.org:liu-21807DiVA, id: diva2:241755
Tillgänglig från: 2009-10-05 Skapad: 2009-10-05 Senast uppdaterad: 2009-10-06

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltext

Personposter BETA

Vikström, Anders

Sök vidare i DiVA

Av författaren/redaktören
Vikström, Anders
Av organisationen
Lungmedicinska kliniken USInstitutionen för klinisk och experimentell medicinHälsouniversitetet
Medicin och hälsovetenskap

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 108 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf